Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

New strategies for targeted payload delivery using small engineered scaffold proteins

Reference number
Coordinator Kungliga Tekniska Högskolan - Skolan för kemi, bioteknologi och hälsa
Funding from Vinnova SEK 9 775 000
Project duration June 2019 - May 2022
Status Ongoing
Venture Protein research and process development within the area of Biologics
Call Protein research and process development for biologics - larger projects

Purpose and goal

The aim of the project is to explore innovative principles that could form the basis in development of next-generation biological drugs against cancer.

Expected results and effects

The project is expected to generate important knowledge on the impact of molecular design of protein-based drugs on their pharmacokinetic and tumour-suppressing properties. The cooperation between academia and industry would result in more efficient development of next-generation drugs by the company Affibody AB, increasing the the competitiveness of Swedish life science industry. The project might have long-term impact on treatment options as well as promoting development of affinity proteins as biopharmaceuticals.

Planned approach and implementation

We will investigate payload therapies against cancer in three subprojects: 1) targeted delivery of cytotoxic drugs and toxins, 2) pretargeting technologies for radiotherapy and 3) prodrug biologics for increased specificity. The studies will be organized in work packages: WP1) molecular design and protein engineering of targeting conjugates, WP2) production, purification and in vitro characterization of targeting conjugates, WP3) pharmacokinetics and preclinical therapy and WP4) industrial implementation and identification of potentially new IP.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 June 2021

Reference number 2019-00104

Page statistics